1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Amrutanjan Health Care Limited

Amrutanjan Health Care Limited

487.65
INR
-8.15
(-1.64%)
18.67EPS
29.19P/E
15.75BMarket Cap
Amrutanjan Health Care Limited
BSE:AMRUTANJAN
(Bombay Stock Exchange)

Recent

price

487.65

P/E

ratio

29.19

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
34.79
48.9
47.09
48.49
56.98
63.08
71.36
74.87
86.2
89.22
113.8
138.51
129.63
144.77
155.83
173.53
176.92
Revenue per Share
3.37
3.3
3.46
4.26
5.1
7.67
7.46
6.83
8.39
8.58
20.94
23
13.65
15.5
17.58
20.03
18.67
Basic EPS, GAAP
-1.51
-0.13
2.49
5.58
4.28
6.56
1.53
5.49
6.54
5.35
30.43
9.84
3.86
7.3
5.31
-6.58
- -
Free Cash Flow per Basic Share
1.75
1.74
1.74
1.75
1.95
3.76
1.4
1.92
1.95
3.15
1.98
4.27
4.94
4.61
4.59
4.57
- -
Dividend per Share
33.46
33
28.14
30.53
32.48
33.6
39.59
44.02
49.86
54.54
73.75
90.87
99.65
99.85
113.02
128.11
- -
Book Value per Share
26.92
26.25
28.01
30.5
32.43
33.52
39.51
43.94
49.71
54.36
73.23
90.07
98.8
99.03
112.42
127.52
- -
Tangible Book Value per Share
30
29
29
29
29
29
29
29
29
29
29
29
29
29
29
29
29
Basic Weighted Avg Shares
1,054
1,429
1,376
1,417
1,666
1,844
2,086
2,188
2,520
2,607
3,325
4,045
3,782
4,201
4,505
5,017
5,115
Sales/Revenue/Turnover
32.55
13.48
10.84
13.44
12.76
16.19
15.06
12.22
11.72
10.32
23.91
20.26
11.12
11.43
11.89
14.15
11.17
Operating Margin (%)
20
37
39
37
32
25
29
31
33
44
37
38
52
61
65
63
67
Depreciation Expense
102
96
101
124
149
224
218
200
245
251
612
672
398
450
508
579
540
Net Income, GAAP
35.03
38.19
34.62
35.79
38.28
35.14
34.16
39.16
28.92
27.2
25.29
25.82
25.74
27.4
26.47
25.64
25.72
Effective Tax Rate (%)
9.69
6.74
7.35
8.78
8.95
12.16
10.45
9.13
9.73
9.62
18.4
16.61
10.53
10.7
11.28
11.54
10.55
Profit Margin (%)
267
240
254
510
570
598
759
890
1,035
868
1,708
1,972
1,969
2,258
2,061
1,655
- -
Working Capital
37
61
- -
- -
- -
- -
- -
- -
- -
11
7
3
4
14
17
14
- -
LT Debt
1,014
965
823
892
950
982
1,157
1,287
1,457
1,594
2,156
2,651
2,908
2,885
3,266
3,702
- -
Total Equity
21.82
9.6
10.12
12.79
15.31
23.92
22.1
15.39
16.5
13.92
30.21
25.31
11.38
12.02
12.92
13.33
- -
Return on Invested Capital (%)
10.42
11.15
11.74
13.9
15.75
22.68
20
16.24
17.91
16.45
32.57
27.98
14.31
15.5
16.48
16.57
- -
Return on Capital (%)
10.32
9.74
11.32
14.51
16.18
23.21
20.38
16.35
17.87
16.44
32.64
27.96
14.33
15.53
16.53
16.62
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
4
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
14
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
19,308
14,303
15,749

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,916
- -
Cash, Cash Equivalents & STI
- -
1,705
- -
Accounts Receivable, Net
- -
606
- -
Inventories
- -
374
- -
Total Current Liabilities
- -
1,262
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
4
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.53%
11.69%
13.35%
Free Cash Flow
36.11%
-58.37%
-224.04%
Net Income, GAAP
16.68%
1.79%
13.93%
Sales/Revenue/Turnover
10.9%
8.96%
11.36%
Total Cash Common Dividend
12.33%
24.54%
-0.52%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
837
1,099
1,228
1,354
4,505
2026
940
1,177
1,410
1,498
5,017
2027
1,030
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.6
4.08
6.66
5.25
17.58
2026
2.87
4.83
6.73
5.6
20.03
2027
1.51
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
4.59
2026
- -
- -
- -
- -
4.57
2027
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Amrutanjan Health Care Limited manufactures and markets a diverse portfolio of Ayurvedic and allopathic healthcare products focused on pain management, cough and cold relief, women's hygiene, and preventive health beverages; core offerings include flagship Amrutanjan Pain Balm in yellow and white variants, roll-ons such as Faster Relaxation and Period Pain Relief, sprays like Advanced Joint Muscle Spray and Joint Muscular Spray, pain patches including Advanced Pain Relief Patch, Relief Cough Syrup and Cough & Cold ColdRub, Comfy sanitary napkins in Snug Fit Regular Cottony and Slim Fit variants, Fruitnik Electro+ electrolyte drinks in low-sugar and ready-to-drink formats, alongside Stop Pain Dental Gel, Decorn Corn Caps, No Germs Hand Sanitizer, Stop Itch, and Relief Hot Drink. The company operates three state-of-the-art manufacturing units in Tamil Nadu and Telangana, distributes through 1,785 distributors to 1.13 million outlets primarily in India with exports to the Gulf, Africa, Southeast Asia, and other international markets including plans for expanded presence in the US and Europe, and maintains an office in Dubai. Founded in 1893 by Kasinadhuni Nageswara Rao in Mumbai and headquartered at No. 103, Luz Church Road, Mylapore, Chennai, Tamil Nadu, the company shifted its headquarters to Chennai in 1914, became a public limited entity named Amrutanjan Limited in 1936, and changed its name to Amrutanjan Health Care Limited in 2007. Recent developments encompass the launch of its first brick-and-mortar Direct-to-Customer store 'World of Amrutanjan' in Delhi during fiscal 2024 with plans for further expansion, appointment of cricketer Ruturaj Gaikwad as brand ambassador for Electro+, approval in May 2024 for a new manufacturing plant, achievement of Comfy as a ₹1 billion brand, 25% sales growth for Electro+, and sustained high double-digit growth in women's hygiene alongside revenue increases to ₹471.82 crore in gross sales and ₹44.97 crore in profit after tax for fiscal 2024.